High concordance of 70‐gene recurrence risk signature and 80‐gene molecular subtyping signature between core needle biopsy and surgical resection specimens in early‐stage breast cancer

Background and Objectives With increased neoadjuvant therapy recommendations for early‐stage breast cancer patients due to the COVID‐19 pandemic, it is imperative that molecular diagnostic assays provide reliable results from preoperative core needle biopsies (CNB). The study objective was to determ...

Full description

Saved in:
Bibliographic Details
Published in:Journal of surgical oncology 2022-03, Vol.125 (4), p.596-602
Main Authors: Crozier, Jennifer A., Barone, Julie, Whitworth, Pat, Cheong, Abraham, Maganini, Robert, Tamayo, Jose Perez, Dauer, Patricia, Wang, Shiyu, Audeh, William, Glas, Annuska M.
Format: Article
Language:English
Subjects:
Adult
Aged
Aged, 80 and over
Biomarkers, Tumor - genetics
Biopsy, Large-Core Needle
BluePrint
Breast
Breast cancer
Breast Neoplasms - genetics
Breast Neoplasms - pathology
Breast Neoplasms - surgery
Clinical Decision Rules
core needle biopsy
COVID-19
COVID‐19 pandemic
Female
genomic profile
Genomics
Humans
MammaPrint
Middle Aged
Neoplasm Staging
Prognosis
Prospective Studies
Reproducibility of Results
Risk Assessment
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Background and Objectives With increased neoadjuvant therapy recommendations for early‐stage breast cancer patients due to the COVID‐19 pandemic, it is imperative that molecular diagnostic assays provide reliable results from preoperative core needle biopsies (CNB). The study objective was to determine the concordance of MammaPrint and BluePrint results between matched CNB and surgical resection (SR) specimens. Methods Matched tumor specimens (n = 121) were prospectively collected from women enrolled in the FLEX trial (NCT03053193). Concordance is reported using overall percentage agreement and Cohen's kappa coefficient. Correlation is reported using Pearson correlation coefficient. Results We found good concordance for MammaPrint results between matched tumor samples (90.9%, κ = 0.817), and a very strong correlation of MammaPrint indices (r = 0.94). The concordance of BluePrint subtyping in matched samples was also excellent (98.3%). Conclusions CNB samples demonstrated high concordance with paired SR samples for MammaPrint risk classification and BluePrint molecular subtyping, suggesting that physicians are provided with accurate prognostic information that can be used to guide therapy decisions.
ISSN:0022-4790
1096-9098
DOI:10.1002/jso.26780